140 related articles for article (PubMed ID: 34571211)
41. Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry.
Fernandez-Sojo J; Horton R; Cid J; Azqueta C; Garcia-Buendia A; Valdivia E; Martorell L; Rubio-Lopez N; Codinach M; Aran G; Marsal J; Mussetti A; Martino R; Diaz-de-Heredia C; Ferra C; Valcarcel D; Linares M; Ancochea A; García-Rey E; García-Muñoz N; Medina L; Carreras E; Villa J; Lozano M; Gibson D; Querol S
Bone Marrow Transplant; 2022 Oct; 57(10):1531-1538. PubMed ID: 35804055
[TBL] [Abstract][Full Text] [Related]
42. Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation.
D'Rozario J; Parisotto R; Stapleton J; Gidley A; Owen D
Transfus Apher Sci; 2014 Jun; 50(3):443-50. PubMed ID: 24680293
[TBL] [Abstract][Full Text] [Related]
43. Cryopreservation of hematopoietic stem/progenitor cells for therapeutic use.
Watt SM; Austin E; Armitage S
Methods Mol Biol; 2007; 368():237-59. PubMed ID: 18080475
[TBL] [Abstract][Full Text] [Related]
44. Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products.
Berens C; Heine A; Müller J; Held SA; Mayer K; Brossart P; Oldenburg J; Pötzsch B; Wolf D; Rühl H
Cytotherapy; 2016 Oct; 18(10):1325-31. PubMed ID: 27491794
[TBL] [Abstract][Full Text] [Related]
45. Sepax-2 cell processing device: a study assessing reproducibility of concentrating thawed hematopoietic progenitor cells.
Mfarrej B; Vicari O; Ouffai S; Malenfant C; Granata A; Thevenet S; Chabannon C; Lemarié C; Calmels B
J Transl Med; 2022 Nov; 20(1):503. PubMed ID: 36329460
[TBL] [Abstract][Full Text] [Related]
46. [Analysis of post-thaw infused cell dose for predicting engraftment after unrelated cord blood transplantation].
Wu JY; Liao C; Chen JS; Xu ZP; Li Y; Sun X; Wu SQ; Tang XW; Lu Y; Xie GE
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):754-8. PubMed ID: 21729565
[TBL] [Abstract][Full Text] [Related]
47. Fresh or Cryopreserved CD34
Ghobadi A; Fiala MA; Ramsingh G; Gao F; Abboud CN; Stockerl-Goldstein K; Uy GL; Grossman BJ; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1072-1077. PubMed ID: 28323004
[TBL] [Abstract][Full Text] [Related]
48. Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the Covid-19 pandemic: A National Marrow Donor Program perspective.
Devine SM
Am J Hematol; 2021 Feb; 96(2):169-171. PubMed ID: 33206414
[No Abstract] [Full Text] [Related]
49. Post-thaw viability of cryopreserved hematopoietic progenitor cell grafts: does it matter?
Vrhovac R; Perić Z; Jurenec S; Kardum-Skelin I; Jelić-Puskarić B; Jaksić B
Coll Antropol; 2010 Mar; 34(1):163-9. PubMed ID: 20432746
[TBL] [Abstract][Full Text] [Related]
50. Donor characteristics and intraoperative total nucleated cell count influence hematopoietic progenitor cell yield of healthy donor bone marrow grafts.
Kalin J; Nguyen ATH; Oshrine B
Pediatr Blood Cancer; 2021 Apr; 68(4):e28902. PubMed ID: 33484054
[TBL] [Abstract][Full Text] [Related]
51. Influence of laboratory procedures on postthawing cell viability and hematopoietic engraftment after autologous peripheral blood stem cell transplantation.
Belisário AR; da Costa Funes AP; Luz JR; de Almeida Costa L; Furtado MDSBS; Martins MC; Cruz NG; Pederzoli PRMP; de Andrade RK; Libânio MRIS; de Lima Prata K
Transfusion; 2021 Apr; 61(4):1202-1214. PubMed ID: 33569783
[TBL] [Abstract][Full Text] [Related]
52. Improved post-thaw recovery of peripheral blood stem/progenitor cells using a novel intracellular-like cryopreservation solution.
Clarke DM; Yadock DJ; Nicoud IB; Mathew AJ; Heimfeld S
Cytotherapy; 2009; 11(4):472-9. PubMed ID: 19499402
[TBL] [Abstract][Full Text] [Related]
53. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease.
Wagner JE; Rosenthal J; Sweetman R; Shu XO; Davies SM; Ramsay NK; McGlave PB; Sender L; Cairo MS
Blood; 1996 Aug; 88(3):795-802. PubMed ID: 8704232
[TBL] [Abstract][Full Text] [Related]
54. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
55. Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products.
Sartor M; Antonenas V; Garvin F; Webb M; Bradstock KF
Bone Marrow Transplant; 2005 Aug; 36(3):199-204. PubMed ID: 15937512
[TBL] [Abstract][Full Text] [Related]
56. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre.
Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M
Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941
[TBL] [Abstract][Full Text] [Related]
57. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.
Kawano Y; Takaue Y; Watanabe A; Takeda O; Arai K; Itoh E; Ohno Y; Teshima T; Harada M; Watanabe T; Okamoto Y; Abe T; Kajiume T; Matsushita T; Ikeda K; Endo M; Kuroda Y; Asano S; Tanosaki R; Yamaguchi K; Law P; McMannis JD
Blood; 1998 Nov; 92(9):3123-30. PubMed ID: 9787147
[TBL] [Abstract][Full Text] [Related]
58. [Umbilical cord blood as a source of stem cells].
Bojanić I; Golubić Cepulić B
Acta Med Croatica; 2006 Jun; 60(3):215-25. PubMed ID: 16933834
[TBL] [Abstract][Full Text] [Related]
59. Clonogenic capacity and ex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation.
Almici C; Carlo-Stella C; Wagner JE; Mangoni L; Garau D; Re A; Giachetti R; Cesana C; Rizzoli V
Bone Marrow Transplant; 1997 Jun; 19(11):1079-84. PubMed ID: 9193749
[TBL] [Abstract][Full Text] [Related]
60. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation.
Konuma T; Kanda J; Uchida N; Nishijima A; Tanaka M; Ozawa Y; Sawa M; Onizuka M; Ota S; Maruyama Y; Kanda Y; Kawakita T; Ara T; Eto T; Nakamae H; Kimura T; Fukuda T; Atsuta Y;
Hematol Oncol; 2023 Feb; 41(1):147-158. PubMed ID: 36268564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
